Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan Injection in Metastatic Prostate Cancer: an Observational, Multicenter, Prospective Cohort Study in China (PSMAreal CN)
Latest Information Update: 24 Dec 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PSMAreal; PSMAreal CN
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 24 Dec 2025 New trial record